Ipamorelin vs Sermorelin

Preclinical evidence from animal models only — not yet shown in humans.

Human data from non-randomized studies: cohorts, case series, case reports.

Ipamorelin is a synthetic pentapeptide ghrelin mimetic that binds the growth hormone secretagogue receptor (GHSR-1a) and tells the pituitary to release GH. Selectivity is its calling card. Where GHRP-2 and GHRP-6 drag cortisol and ACTH up alongside GH, ipamorelin — in animal studies — lifts GH without significantly moving ACTH or cortisol beyond what GHRH itself does. It also barely touches appetite compared to MK-677, a difference that comes down to how it sits on the receptor. In animal work it usually shares the syringe with a GHRH analog like CJC-1295, the idea being that hitting the GHRH receptor and the GHSR at once amplifies the GH pulse more than either alone.

Sermorelin is the acetate salt of GHRH(1-29)NH2, the active N-terminal piece of the body's own growth hormone-releasing hormone. It binds pituitary GHRH receptors and triggers physiological, pulsatile GH release, keeping the normal GH–somatostatin–IGF-1 feedback loop intact in a way that straight GH replacement does not. The trade-off is duration: its half-life runs in minutes, not the hours of tesamorelin or CJC-1295, so it needs frequent dosing to keep the pituitary engaged. And it cannot push GH past what the gland is willing to make — a safety feature and a hard ceiling on effect, at the same time.

GH / IGF-1 support, Body composition

GH / IGF-1 support, Body composition, Sleep & recovery

Sold "for research use only" — not approved for human consumption.

Available in the US only via prescription or a compounding pharmacy.